News of Note—Sanofi's Dengvaxia, HPV vaccine and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week.

> Dengvaxia's safety scandal in the Philippines lowered confidence in vaccines overall in the country. Release

> A study found that teenage girls are not more likely to engage in risky sexual behavior if they receive the HPV vaccine. Newsweek article

> Inovio Pharmaceuticals' Ebola vaccine candidate elicited immune responses in a preclinical study. Release

> The Walter Reed Army Institute of Research kicked off an early stage trial of a vaccine candidate against Marburg virus. Release

> Valneva advanced its Chikungunya vaccine candidate to the next stage within a phase 1 trial program. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.